上海锐信生物技术有限公司
Shanghai Ruixin Biotechnology Co., Ltd.
产品详情
分享到：

P3 Prim. Cell 4D-NucleofectorLV Kit L

13800000000
产品详情
品牌 LONZA 货号 V4LP-3002
规格 KIT 类型 试剂
运输条件 4℃~8℃ 储存条件 4℃~8℃
货期 请咨询

P3 Primary Cell 4D-NucleofectorTM LV Kit L

Catalog #: V4LP-3002
For larger scale transfection of primary cells, e.g. human T cells or CD34+ hematopoietic stem cells in the 1 mL NucleocuvetteTM Cartridge format when working with the 4D-NucleofectorTM LV Unit
Product Overview

The P3 Primary Cell 4D-NucleofectorTM LV Kit L is suited for larger scale transfection of primary cells in the 1 mL NucleocuvetteTM Cartridge format when working with the 4D-NucleofectorTM LV Unit. With the 1 mL NucleocuvetteTM Cartridge a fixed volume of 1 mL can be transfected. The cartridge is manually filled via a sterile injection port.

This kit has been determined to be optimal for transfecting following primary cells and many others that use Solution P3 as optimal NucleofectorTM Solution:

  • B cell (human)

  • CD34+ cell (human)

  • DC (human)

  • ES (human), H9

  • Macrophage (human)

  • Monocyte (human)

  • T cell (human), stim.

  • T cell (mouse), unstim.

The respective cell type-specific Optimized Protocols or recommendations are available under "Instructions" or in our knowledge database. In these Optimized Protocols the best Nucleofection conditions are indicated. In addition, we share our experience and knowledge for treatment of individual cell types.

*Note: From the five primary cell solutions (P1 – P5) that come with the 4D-NucleofectorTM System only P3 is available for the large-scale formats so far. Solution P3 is suited for most immune and stem cells (e.g. T cells, dendritic cells, CD34 hematopoietic stem cells). For other solutions please contact our Scientific Support.

Benefits

  • -Closed Nucleofection of up to 108 primary cells

  • -Conditions transferable from existing smaller scale protocols

  • -Simple manual filling via sterile injection port

  • -Transfection within seconds

Applications

  • -For large scale transfection of up to 1 x 108 cells

  • -Ex-vivo modification of human primary cells for the development and establishment of cell therapy applications (e.g. genome editing generation of CAR-T cells)

  • -Generation of large numbers of transiently modified primary cells for cell-based assays

Content & Storage

Content

2.25 mL P3 Primary Cell NucleofectorTM Solution

0.5 mL Supplement 1

50 µg pmaxGFPTM Vector (1 μg/μl in 10 mM Tris pH 8.0)

2 x 1 mL NucleocuvetteTM Cartridge